Amneal Ready To Go Head-To-Head With Mylan’s Xulane In US

Gains 180 Days Of CGT Exclusivity For Generic Of Ortho Evra Contraceptive Patch

Amneal is set to benefit from 180 days of US exclusivity for its norelgestromin and ethinyl estradiol contraceptive patch product after receiving FDA approval with a competitive generic therapy designation. The generic will be the only competitor to Mylan’s Xulane version.

Number 180 red white
Amneal will benefit from 180 days of CGT exclusivity • Source: Shutterstock

Amneal has received approval for and is launching today its US generic version of Janssen’s Ortho Evra (norelgestromin/ethinyl estradiol) 150mcg/35mcg contraceptive patches.

The firm is set to benefit from 180 days of exclusivity after the US Food and Drug Administration approved the...

Generics Bulletin Podcast

Stay ahead of every shift in generics and biosimilars.

Generics Bulletin brings you the latest updates that matter for the off-patent industry.

More from Products

More from Generics Bulletin